Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland. 

Specialists in controlled substance development and manufacturing, Noramco is a partner to the pharmaceutical industry:

– Focusing on  high-purity controlled substances
– Leveraging intellectual property to devise the most efficient routes to APIs
– Providing analytical data, chemical and physical properties, stability studies and regulatory assistance
– Formulation friendly particle size grades and extended technical packages
– Delivering DEA-compliant security and production capacity, from kilos to multi-ton supply
– Supporting world-class supply security of controlled-substances, from schedule I to schedule III

Chemicals

Manufacturing

Pharmaceutical

Noramco™

Alan Majewski

Joseph Marsh

Bryan Proulx

Andrew Pierce

Alexandra V.

Keith Taylor

Anthony Smith

Jonathan Laskos

Anthony Ambrosini

Mathew Minardi

Scott Warner

Bill Grubb

Engineering and Technical Specialists

Research and Development Team

Leadership Team

Finance and Accounting

Quality Assurance and Regulatory Compliance

Sales and Business Development

Facilities and Maintenance Team

Teams at Noramco™